Vergelijking
LL-37 vs. Octreotide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
597562-32-8
83150-76-9
Molecuulmassa
4493.33 g/mol
1019.24 g/mol
Halfwaardetijd
geen gegevens
1.7 h
Sequentie
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESD-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Werkingsmechanisme
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
5
waarvan bij mensen
1
4
Geregistreerde effecten
4
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
0
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between LL-37 and Octreotide?
- LL-37 is classified as "Onderzoek (overig)", while Octreotide is classified as "Onderzoek (overig)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Octreotide?
- The highest available evidence level is "Humane studie" for LL-37 and "Humane RCT" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Octreotide in Germany and the United States?
- Duitsland: LL-37 — Alleen onderzoek, Octreotide — Op recept. Verenigde Staten: LL-37 — Alleen onderzoek, Octreotide — Op recept. These are factual summaries with source and review date on the individual pages.